Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income

Reuters

09/26

Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income

Sunho Biologics Inc. released its Interim Report 2025, providing an update on its financial performance for the six months ended June 30, 2025. During the reporting period, the company recorded other income of RMB5.04 million, compared to RMB1.78 million for the same period in 2024, representing an increase of 178%. The increase was mainly attributed to higher interest income from financial institutions, which rose to RMB5.02 million from RMB1.74 million in the prior year period. Government grants received during the period totaled RMB17,000, down from RMB38,000 in the previous year. No significant events affecting business operations were reported after the end of the reporting period up to September 16, 2025. The company did not provide an outlook or guidance in the disclosed segments of the report.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunho Biologics Inc. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2570889183"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570889183\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570889183?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-26 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570889183","market":"fut","top_or_hot":-1,"title":"Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sunho Biologics Inc. released its Interim Report 2025, providing an update on its financial performance for the six months ended June 30, 2025. During the reporting period, the company recorded other income of RMB5.04 million, compared to RMB1.78 million for the same period in 2024, representing an increase of 178%. The increase was mainly attributed to higher interest income from financial institutions, which rose to RMB5.02 million from RMB1.74 million in the prior year period. Government grants received during the period totaled RMB17,000, down from RMB38,000 in the previous year. No significant events affecting business operations were reported after the end of the reporting period up to September 16, 2025. The company did not provide an outlook or guidance in the disclosed segments of the report.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunho Biologics Inc. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-26 21:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sunho Biologics Inc. released its Interim Report 2025, providing an update on its financial performance for the six months ended June 30, 2025. During the reporting period, the company recorded other income of RMB5.04 million, compared to RMB1.78 million for the same period in 2024, representing an increase of 178%. The increase was mainly attributed to higher interest income from financial institutions, which rose to RMB5.02 million from RMB1.74 million in the prior year period. Government grants received during the period totaled RMB17,000, down from RMB38,000 in the previous year. No significant events affecting business operations were reported after the end of the reporting period up to September 16, 2025. The company did not provide an outlook or guidance in the disclosed segments of the report.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunho Biologics Inc. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02898","symbol_name":"盛禾生物-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDL9dKpSd:1","article_id":"2570889183","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570889183","pubTimestamp":1758892780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sunho Biologics Inc. released its Interim Report 2025, providing an update on its financial performance for the six months ended June 30, 2025. During the reporting period, the company recorded other income of RMB5.04 million, compared to RMB1.78 million for the same period in 2024, representing an increase of 178%. The increase was mainly attributed to higher interest income from financial institutions, which rose to RMB5.02 million from RMB1.74 million in the prior year period. Government grants received during the period totaled RMB17,000, down from RMB38,000 in the previous year. No significant events affecting business operations were reported after the end of the reporting period up to September 16, 2025. The company did not provide an outlook or guidance in the disclosed segments of the report.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02898":"盛禾生物-B","BK1161":"生物科技"},"translate_title":"Sunho Biologics报告称，在利息收入增加的推动下，2025年上半年其他收入增长178%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02898":0.9},"content_text":"Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income\n    \n\n        Sunho Biologics Inc. released its Interim Report 2025, providing an update on its financial performance for the six months ended June 30, 2025. During the reporting period, the company recorded other income of RMB5.04 million, compared to RMB1.78 million for the same period in 2024, representing an increase of 178%. The increase was mainly attributed to higher interest income from financial institutions, which rose to RMB5.02 million from RMB1.74 million in the prior year period. Government grants received during the period totaled RMB17,000, down from RMB38,000 in the previous year. No significant events affecting business operations were reported after the end of the reporting period up to September 16, 2025. The company did not provide an outlook or guidance in the disclosed segments of the report.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunho Biologics Inc. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}